Glenn F. Tilton - Apr 28, 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
Director
Signature
Steven L. Scrogham, attorney-in-fact for Glenn F. Tilton
Stock symbol
ABBV
Transactions as of
Apr 28, 2023
Transactions value $
-$336,998
Form type
4
Date filed
5/2/2023, 05:17 PM
Previous filing
Jan 19, 2023
Next filing
May 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Stock Equivalent Units Options Exercise -$337K -2.23K -6.04% $151.12 34.7K Apr 28, 2023 Common Stock 2.23K $151.12 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The cash equivalent of 2,230 AbbVie stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on April 28, 2023.
F2 Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.